HOME >Volume 2,Issue 1,2019


Background: Global estimates show that by 2,035 we will have about 592 million diabetic patients, with a major impact on low- and middle-income countries. Pancreas and pancreatic islet transplantation are currently the only available therapeutic alternatives capable of restoring the physiological pattern of insulin secretion in diabetic patients. However, because the rate of pancreas transplantation is still very low in the country, a more comprehensive criterion for donor acceptance has been proposed. The therapeutic procedure for transplantation of pancreatic islet is approved in Canada and it is in the approval phase in the United States and in experimental phase in Brazil. Despite the fact that the procedure is minimally invasive, consisting of islet infusion into the hepatic parenchyma by ultrasound-guided transcutaneous catheterization, it was observed that both the function and the survival of the islet deteriorate with time, due to factors related to the revascularization of the grafts. In addition, long-term follow-up allowed the identification of late side effects, such as the development of foci of hepatic steatosis. Aims: To investigate the state of knowledge of pancreatic islet transplantation in murine experimental models. Materials and Methods: A critical analysis of PubMed®- indexed publications from 2000 to May 2019 was performed, associating the following descriptors: "pancreatic islet transplantation", "proliferation", "beta-cell". Results: Of the total of 225 publications, 23 publications were obtained, whose summary or complete access was validated by correlation with the theme. Full articles have been reviewed and references were used to identify other sources of information. Conclusion: The state of the art in transplantation of pancreatic islets, in murine experimental models and their translational use, still present pending questions. Researchers advocate the need for well-designed, and statistically significant prospective studies aimed at solving basic and fundamental issues such as immune tolerance. However, it is believed that in the near future, cell replacement therapy will benefit a greater number of diabetic patients.